Does Gender Influence the Cardiovascular Benefits Observed With Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors? A Meta-Regression Analysis

Cardiology and Therapy
doi 10.1007/s40119-016-0075-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pdb1 - Acute Renal Outcomes With Sodium Glucose Co-Transporter 2 Inhibitors- Real World Data Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through?

Anaesthesia
AnesthesiologyPain Medicine
2019English

Sodium–glucose Co-Transporter 2 Inhibitors: Think Twice About Diabetic Ketoacidosis

2018English

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally

US Endocrinology
EndocrinologyMetabolismDiabetes
2017English

Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through? A Reply

Anaesthesia
AnesthesiologyPain Medicine
2019English

Sodium-Glucose Co-Transporter Type-2 Inhibitors: Pharmacology and Peri-Operative Considerations

Anaesthesia
AnesthesiologyPain Medicine
2018English

Sodium-Glucose Co-Transporter 2 Inhibitors: A Review of Their Use in Older People With Type 2 Diabetes Mellitus

Journal of Pharmacy Practice and Research
PharmacologyPharmacy
2016English

Cardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2018English

Sodium-Glucose Co-Transporter 2 Inhibitors in the Peri-Operative Period: A Warning to All Clinicians

BJU International
Urology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy